SCHEDULE: Bering Partners Discloses 6.5% Stake in Coherus Oncology

Bering Partners II, L.P., Bering Partners III, L.P., and their managing members, Evgeny Zaytsev and Philip Sawyer, have disclosed beneficial ownership of 6.5% of Coherus Oncology, Inc.'s common stock.

Summary

• Bering Partners II, L.P. beneficially owns 4,763,062 shares of Coherus Oncology, Inc. common stock, representing 4.1% of the class.
• Bering Partners III, L.P. beneficially owns 2,826,446 shares of Coherus Oncology, Inc. common stock, representing 2.4% of the class. This includes 1,274,623 shares issuable upon the exercise of a warrant.
• Evgeny Zaytsev, a managing member of the general partners for both Bering II and Bering III, beneficially owns an aggregate of 7,602,708 shares, representing 6.5% of the class. This includes 13,200 shares directly owned by Zaytsev and shared voting/dispositive power over shares held by Bering II and Bering III.
• Philip Sawyer, also a managing member, beneficially owns an aggregate of 7,589,508 shares, representing 6.5% of the class, with shared voting/dispositive power over shares held by Bering II and Bering III.
• The total outstanding shares of Coherus Oncology, Inc. common stock used for calculation were 116,227,275 as of July 31, 2025.
• The shares were not acquired for the purpose of changing or influencing control of the issuer, indicating a passive investment.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by Bering Partners in Coherus Oncology, which can be viewed as a vote of confidence. However, it does not contain operational or financial performance data to assess company health, leading to a neutral to slightly positive sentiment.

Positives

• Increased institutional ownership by Bering Partners, potentially signaling confidence in Coherus Oncology.
• The investment is stated to be passive, not intended to influence control, which can reduce concerns about activist investor actions.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership. May be perceived positively as a vote of confidence.
• Management: Awareness of a significant passive investor, though no direct impact on control or operations is indicated.

Key Dates

Recommendation

This filing is a Schedule 13G, which is a passive ownership disclosure. It reveals that Bering Partners, through various entities and individuals, holds a 6.5% stake in Coherus Oncology. While the presence of a significant institutional investor can be seen as a positive signal, the filing itself does not contain financial performance, strategic updates, or other operational details necessary to form a definitive 'buy' or 'sell' recommendation. The stated passive nature of the investment further limits its direct implications for immediate stock performance beyond the initial market reaction to the ownership disclosure. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting more comprehensive financial or strategic updates from the company.

Keywords

Coherus Oncology, CHRS, Bering Partners, Evgeny Zaytsev, Philip Sawyer, Schedule 13G, beneficial ownership, institutional investment, passive investment